Literature DB >> 31495407

2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension: The European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT.

Georg Hansmann1, Martin Koestenberger2, Tero-Pekka Alastalo3, Christian Apitz4, Eric D Austin5, Damien Bonnet6, Werner Budts7, Michele D'Alto8, Michael A Gatzoulis9, Babar S Hasan10, Rainer Kozlik-Feldmann11, R Krishna Kumar12, Astrid E Lammers13, Heiner Latus14, Ina Michel-Behnke15, Oliver Miera16, Nicholas W Morrell17, Guido Pieles18, Daniel Quandt19, Hannes Sallmon20, Dietmar Schranz21, Karin Tran-Lundmark22, Robert M R Tulloh23, Gregor Warnecke24, Håkan Wåhlander25, Sven C Weber20, Peter Zartner26.   

Abstract

The European Pediatric Pulmonary Vascular Disease Network is a registered, non-profit organization that strives to define and develop effective, innovative diagnostic methods and treatment options in all forms of pediatric pulmonary hypertensive vascular disease, including pulmonary hypertension (PH) associated with bronchopulmonary dysplasia, PH associated with congenital heart disease (CHD), persistent PH of the newborn, and related cardiac dysfunction. The executive writing group members conducted searches of the PubMed/MEDLINE bibliographic database (1990-2018) and held face-to-face and web-based meetings. Ten section task forces voted on the updated recommendations, based on the 2016 executive summary. Clinical trials, meta-analyses, guidelines, and other articles that include pediatric data were searched using the term "pulmonary hypertension" and other keywords. Class of recommendation (COR) and level of evidence (LOE) were assigned based on European Society of Cardiology/American Heart Association definitions and on pediatric data only, or on adult studies that included >10% children or studies that enrolled adults with CHD. New definitions by the World Symposium on Pulmonary Hypertension 2018 were included. We generated 10 tables with graded recommendations (COR/LOE). The topics include diagnosis/monitoring, genetics/biomarkers, cardiac catheterization, echocardiography, cardiac magnetic resonance/chest computed tomography, associated forms of PH, intensive care unit/lung transplantation, and treatment of pediatric PH. For the first time, a set of specific recommendations on the management of PH in middle- and low-income regions was developed. Taken together, these executive, up-to-date guidelines provide a specific, comprehensive, detailed but practical framework for the optimal clinical care of children and young adults with PH.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  European Pediatric Pulmonary Vascular Disease Network; children; congenital heart disease; guidelines; pediatric; pulmonary hypertension; pulmonary vascular disease; right heart failure; right ventricle

Mesh:

Year:  2019        PMID: 31495407     DOI: 10.1016/j.healun.2019.06.022

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  50 in total

1.  Association of Preoperative Mixed Venous Oxygen Saturation with Postoperative Segmental Pulmonary Hypertension in Pulmonary Atresia with Ventricular Septal Defect and Major Aortopulmonary Collaterals.

Authors:  Taiyu Hayashi; Hiroshi Ono; Yukihiro Kaneko
Journal:  Pediatr Cardiol       Date:  2020-07-24       Impact factor: 1.655

2.  Optimal Oxygen Targets in Term Lambs with Meconium Aspiration Syndrome and Pulmonary Hypertension.

Authors:  Munmun Rawat; Praveen Chandrasekharan; Sylvia F Gugino; Carmon Koenigsknecht; Lori Nielsen; Stephen Wedgwood; Bobby Mathew; Jayasree Nair; Robin Steinhorn; Satyan Lakshminrusimha
Journal:  Am J Respir Cell Mol Biol       Date:  2020-10       Impact factor: 6.914

Review 3.  Activation of the Metabolic Master Regulator PPARγ: A Potential PIOneering Therapy for Pulmonary Arterial Hypertension.

Authors:  Georg Hansmann; Laurent Calvier; Michael G Risbano; Stephen Y Chan
Journal:  Am J Respir Cell Mol Biol       Date:  2020-02       Impact factor: 6.914

4.  Relationship Between Left Ventricular Geometry and Invasive Hemodynamics in Pediatric Pulmonary Hypertension.

Authors:  Dale A Burkett; Sonali S Patel; Luc Mertens; Mark K Friedberg; D Dunbar Ivy
Journal:  Circ Cardiovasc Imaging       Date:  2020-05-15       Impact factor: 7.792

5.  Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension.

Authors:  Sabrina Schweintzger; Martin Koestenberger; Axel Schlagenhauf; Gernot Grangl; Ante Burmas; Stefan Kurath-Koller; Mirjam Pocivalnik; Hannes Sallmon; Daniela Baumgartner; Georg Hansmann; Andreas Gamillscheg
Journal:  Cardiovasc Diagn Ther       Date:  2020-10

6.  Prognostic Value of Change in Cardiac Index After Prostacyclin Initiation in Pediatric Pulmonary Hypertension.

Authors:  Patrick D Evers; Paul J Critser; Michelle Cash; Melissa Magness; Russel Hirsch
Journal:  Pediatr Cardiol       Date:  2020-09-24       Impact factor: 1.655

7.  Children with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension Treated with Pulmonary Vasodilators-The Pediatric Cardiologist Point of View.

Authors:  Anna Migdał; Anna Sądel-Wieczorek; Edyta Ryciak; Alicja Mirecka-Rola; Grażyna Brzezińska-Rajszys; Małgorzata Żuk
Journal:  Children (Basel)       Date:  2021-04-22

Review 8.  Pulmonary hypertension in the child with bronchopulmonary dysplasia.

Authors:  Kelsey W Malloy; Eric D Austin
Journal:  Pediatr Pulmonol       Date:  2021-08-05

9.  Diffuse midline glioma presenting with central sleep apnea and pulmonary hypertension in a 4-year-old patient: a case report.

Authors:  Szu-Wei Huang; Pei-Lin Lee; Pi-Chuan Fan; Meng-Fai Kuo; Chun-An Chen; Shuenn-Nan Chiu; Ming-Tai Lin; Chun-Wei Lu; Jou-Kou Wang; Mei-Hwan Wu
Journal:  J Clin Sleep Med       Date:  2021-02-01       Impact factor: 4.062

10.  Dysregulated lncRNA TUG1 in different pulmonary artery cells under hypoxia.

Authors:  Zhenchun Lv; Rong Jiang; Xiaoyi Hu; Qinhua Zhao; Yuanyuan Sun; Lan Wang; Jinling Li; Yuqing Miao; Wenhui Wu; Ping Yuan
Journal:  Ann Transl Med       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.